The GNAQ gene discovery for the cause of Sturge-Weber syndrome in May 2013 was not only historic but cause for renewed hope around the world for parents and individuals living with SWS. The discovery gave clinicians and scientists a road map to forge new studies and investigations for therapeutic interventions. Now more than ever is the time for all concerned to make a renewed commitment to fostering and funding clinical trials to increase the pace of drug development.
We hope you find the following information enlightening, thought provoking and that it creates a spark of activity for you to participate in any or all phases of SWS or birthmark clinical trials and drug development. Please continue to dialogue with the SWF and together we will leave a lasting legacy.
Mennato Forgione started his career at the "Bambino Gesu`" Children's Hospital in Rome, Italy and later led the technical team of the Comprehensive Epilepsy Center at Columbia Presbyterian Hospital in New York from 1991 to 2000. Mennato is well acquainted with the clinical drug development process, from his experience in selling medical/diagnostic devices and CRO services for the last 14 years. In his current role, he provides Bio-Pharmaceutical clients with Ce3's arrays of key services and customized solution to their clinical development challenges in this highly regulated environment.